Financhill
Sell
2

TECX Quote, Financials, Valuation and Earnings

Last price:
$25.29
Seasonality move :
-8.25%
Day range:
$24.50 - $26.18
52-week range:
$13.80 - $61.07
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.48x
Volume:
269.5K
Avg. volume:
508.1K
1-year change:
59.68%
Market cap:
$373.2M
Revenue:
--
EPS (TTM):
-$3.45

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
TECX
Tectonic Therapeutic
-- -- -- -50.01% $85.67
AIM
AIM ImmunoTech
$100K -$0.09 -23.08% -53.85% $2.75
CI
The Cigna Group
$63.2B $7.82 9.16% 124.09% $362.31
CVM
CEL-SCI
-- -- -- -- $7.40
IGC
IGC Pharma
$204K -$0.03 -- -25% $4.25
TMCI
Treace Medical Concepts
$67.2M -$0.04 5.01% -6.67% $10.91
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
TECX
Tectonic Therapeutic
$25.29 $85.67 $373.2M -- $0.00 0% --
AIM
AIM ImmunoTech
$0.14 $2.75 $8.6M -- $0.00 0% 37.10x
CI
The Cigna Group
$308.85 $362.31 $84.5B 25.23x $1.40 1.81% 0.36x
CVM
CEL-SCI
$0.33 $7.40 $25.5M -- $0.00 0% --
IGC
IGC Pharma
$0.29 $4.25 $23.1M -- $0.00 0% 17.05x
TMCI
Treace Medical Concepts
$8.94 $10.91 $559.8M -- $0.00 0% 2.65x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
TECX
Tectonic Therapeutic
-- 3.524 -- --
AIM
AIM ImmunoTech
48.41% 1.568 17.25% 0.71x
CI
The Cigna Group
43.79% 1.200 42.17% 0.77x
CVM
CEL-SCI
-- 1.534 -- --
IGC
IGC Pharma
2.1% -1.752 0.51% 0.21x
TMCI
Treace Medical Concepts
32.07% 4.961 11.49% 3.34x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
TECX
Tectonic Therapeutic
-- -$19.6M -- -- -- -$42.4M
AIM
AIM ImmunoTech
$27K -$4.5M -219.06% -256.33% -9994.29% -$3.3M
CI
The Cigna Group
-- -- 4.6% 8.07% 3.61% $4.9B
CVM
CEL-SCI
-- -$6.9M -- -- -- -$4.2M
IGC
IGC Pharma
$104K -$1.9M -114.2% -116.24% -730.74% -$1.4M
TMCI
Treace Medical Concepts
$55.5M -$204K -32.41% -46.9% 1.18% -$7.3M

Tectonic Therapeutic vs. Competitors

  • Which has Higher Returns TECX or AIM?

    AIM ImmunoTech has a net margin of -- compared to Tectonic Therapeutic's net margin of -10571.43%. Tectonic Therapeutic's return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    TECX
    Tectonic Therapeutic
    -- -$1.20 --
    AIM
    AIM ImmunoTech
    77.14% -$0.06 $5.6M
  • What do Analysts Say About TECX or AIM?

    Tectonic Therapeutic has a consensus price target of $85.67, signalling upside risk potential of 238.68%. On the other hand AIM ImmunoTech has an analysts' consensus of $2.75 which suggests that it could grow by 1937.04%. Given that AIM ImmunoTech has higher upside potential than Tectonic Therapeutic, analysts believe AIM ImmunoTech is more attractive than Tectonic Therapeutic.

    Company Buy Ratings Hold Ratings Sell Ratings
    TECX
    Tectonic Therapeutic
    3 0 0
    AIM
    AIM ImmunoTech
    1 0 0
  • Is TECX or AIM More Risky?

    Tectonic Therapeutic has a beta of 1.289, which suggesting that the stock is 28.926% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.411, suggesting its less volatile than the S&P 500 by 58.887%.

  • Which is a Better Dividend Stock TECX or AIM?

    Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TECX or AIM?

    Tectonic Therapeutic quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Tectonic Therapeutic's net income of -$17.7M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus 37.10x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TECX
    Tectonic Therapeutic
    -- -- -- -$17.7M
    AIM
    AIM ImmunoTech
    37.10x -- $35K -$3.7M
  • Which has Higher Returns TECX or CI?

    The Cigna Group has a net margin of -- compared to Tectonic Therapeutic's net margin of 2.17%. Tectonic Therapeutic's return on equity of -- beat The Cigna Group's return on equity of 8.07%.

    Company Gross Margin Earnings Per Share Invested Capital
    TECX
    Tectonic Therapeutic
    -- -$1.20 --
    CI
    The Cigna Group
    -- $5.13 $73.2B
  • What do Analysts Say About TECX or CI?

    Tectonic Therapeutic has a consensus price target of $85.67, signalling upside risk potential of 238.68%. On the other hand The Cigna Group has an analysts' consensus of $362.31 which suggests that it could grow by 17.31%. Given that Tectonic Therapeutic has higher upside potential than The Cigna Group, analysts believe Tectonic Therapeutic is more attractive than The Cigna Group.

    Company Buy Ratings Hold Ratings Sell Ratings
    TECX
    Tectonic Therapeutic
    3 0 0
    CI
    The Cigna Group
    13 5 0
  • Is TECX or CI More Risky?

    Tectonic Therapeutic has a beta of 1.289, which suggesting that the stock is 28.926% more volatile than S&P 500. In comparison The Cigna Group has a beta of 0.527, suggesting its less volatile than the S&P 500 by 47.338%.

  • Which is a Better Dividend Stock TECX or CI?

    Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cigna Group offers a yield of 1.81% to investors and pays a quarterly dividend of $1.40 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. The Cigna Group pays out 45.63% of its earnings as a dividend. The Cigna Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios TECX or CI?

    Tectonic Therapeutic quarterly revenues are --, which are smaller than The Cigna Group quarterly revenues of $65.7B. Tectonic Therapeutic's net income of -$17.7M is lower than The Cigna Group's net income of $1.4B. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while The Cigna Group's PE ratio is 25.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus 0.36x for The Cigna Group. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TECX
    Tectonic Therapeutic
    -- -- -- -$17.7M
    CI
    The Cigna Group
    0.36x 25.23x $65.7B $1.4B
  • Which has Higher Returns TECX or CVM?

    CEL-SCI has a net margin of -- compared to Tectonic Therapeutic's net margin of --. Tectonic Therapeutic's return on equity of -- beat CEL-SCI's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    TECX
    Tectonic Therapeutic
    -- -$1.20 --
    CVM
    CEL-SCI
    -- -$0.11 --
  • What do Analysts Say About TECX or CVM?

    Tectonic Therapeutic has a consensus price target of $85.67, signalling upside risk potential of 238.68%. On the other hand CEL-SCI has an analysts' consensus of $7.40 which suggests that it could grow by 2142.42%. Given that CEL-SCI has higher upside potential than Tectonic Therapeutic, analysts believe CEL-SCI is more attractive than Tectonic Therapeutic.

    Company Buy Ratings Hold Ratings Sell Ratings
    TECX
    Tectonic Therapeutic
    3 0 0
    CVM
    CEL-SCI
    1 0 0
  • Is TECX or CVM More Risky?

    Tectonic Therapeutic has a beta of 1.289, which suggesting that the stock is 28.926% more volatile than S&P 500. In comparison CEL-SCI has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.414%.

  • Which is a Better Dividend Stock TECX or CVM?

    Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TECX or CVM?

    Tectonic Therapeutic quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Tectonic Therapeutic's net income of -$17.7M is lower than CEL-SCI's net income of -$7.1M. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TECX
    Tectonic Therapeutic
    -- -- -- -$17.7M
    CVM
    CEL-SCI
    -- -- -- -$7.1M
  • Which has Higher Returns TECX or IGC?

    IGC Pharma has a net margin of -- compared to Tectonic Therapeutic's net margin of -711.67%. Tectonic Therapeutic's return on equity of -- beat IGC Pharma's return on equity of -116.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    TECX
    Tectonic Therapeutic
    -- -$1.20 --
    IGC
    IGC Pharma
    40.47% -$0.02 $6.4M
  • What do Analysts Say About TECX or IGC?

    Tectonic Therapeutic has a consensus price target of $85.67, signalling upside risk potential of 238.68%. On the other hand IGC Pharma has an analysts' consensus of $4.25 which suggests that it could grow by 1365.52%. Given that IGC Pharma has higher upside potential than Tectonic Therapeutic, analysts believe IGC Pharma is more attractive than Tectonic Therapeutic.

    Company Buy Ratings Hold Ratings Sell Ratings
    TECX
    Tectonic Therapeutic
    3 0 0
    IGC
    IGC Pharma
    1 0 0
  • Is TECX or IGC More Risky?

    Tectonic Therapeutic has a beta of 1.289, which suggesting that the stock is 28.926% more volatile than S&P 500. In comparison IGC Pharma has a beta of 1.213, suggesting its more volatile than the S&P 500 by 21.346%.

  • Which is a Better Dividend Stock TECX or IGC?

    Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TECX or IGC?

    Tectonic Therapeutic quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $257K. Tectonic Therapeutic's net income of -$17.7M is lower than IGC Pharma's net income of -$1.8M. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus 17.05x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TECX
    Tectonic Therapeutic
    -- -- -- -$17.7M
    IGC
    IGC Pharma
    17.05x -- $257K -$1.8M
  • Which has Higher Returns TECX or TMCI?

    Treace Medical Concepts has a net margin of -- compared to Tectonic Therapeutic's net margin of -0.73%. Tectonic Therapeutic's return on equity of -- beat Treace Medical Concepts's return on equity of -46.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    TECX
    Tectonic Therapeutic
    -- -$1.20 --
    TMCI
    Treace Medical Concepts
    80.74% -$0.01 $166.2M
  • What do Analysts Say About TECX or TMCI?

    Tectonic Therapeutic has a consensus price target of $85.67, signalling upside risk potential of 238.68%. On the other hand Treace Medical Concepts has an analysts' consensus of $10.91 which suggests that it could grow by 22.08%. Given that Tectonic Therapeutic has higher upside potential than Treace Medical Concepts, analysts believe Tectonic Therapeutic is more attractive than Treace Medical Concepts.

    Company Buy Ratings Hold Ratings Sell Ratings
    TECX
    Tectonic Therapeutic
    3 0 0
    TMCI
    Treace Medical Concepts
    2 5 0
  • Is TECX or TMCI More Risky?

    Tectonic Therapeutic has a beta of 1.289, which suggesting that the stock is 28.926% more volatile than S&P 500. In comparison Treace Medical Concepts has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock TECX or TMCI?

    Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Treace Medical Concepts offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. Treace Medical Concepts pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TECX or TMCI?

    Tectonic Therapeutic quarterly revenues are --, which are smaller than Treace Medical Concepts quarterly revenues of $68.7M. Tectonic Therapeutic's net income of -$17.7M is lower than Treace Medical Concepts's net income of -$501K. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while Treace Medical Concepts's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus 2.65x for Treace Medical Concepts. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TECX
    Tectonic Therapeutic
    -- -- -- -$17.7M
    TMCI
    Treace Medical Concepts
    2.65x -- $68.7M -$501K

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Palantir Stock Overhyped?
Is Palantir Stock Overhyped?

At one point, it seemed like the software giant Palantir…

Is Texas Roadhouse a Buy, Sell or Hold?
Is Texas Roadhouse a Buy, Sell or Hold?

Texas Roadhouse (NASDAQ:TXRH) is a popular chain of steakhouses with…

New Billion Dollar Contract Surprises GEO Analysts
New Billion Dollar Contract Surprises GEO Analysts

While earnings appeared mixed at first glance, management’s comments on…

Stock Ideas

Buy
61
Is AAPL Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 40x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 42x

Sell
46
Is MSFT Stock a Buy?

Market Cap: $3T
P/E Ratio: 34x

Alerts

Sell
10
PRAX alert for Mar 1

Praxis Precision Medicines [PRAX] is down 40.97% over the past day.

Sell
22
ACHC alert for Mar 1

Acadia Healthcare [ACHC] is down 25.48% over the past day.

Buy
75
GRRR alert for Mar 1

Gorilla Technology Group [GRRR] is up 21.83% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock